WHO ICTRP trial
Moderna TX
PACTR202212801139469 · Pan African Clinical Trials Registry (PACTR) · Not Recruiting
Key facts
| Trial ID | PACTR202212801139469 |
|---|---|
| Public title | Moderna TX |
| Scientific title | A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled, Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to < 18 years of age |
| Primary sponsor | Moderna TX Inc |
| Registry | Pan African Clinical Trials Registry (PACTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase-2 |
| Countries | Kenya;Kenya;Kenya;Kenya;Kenya;Kenya;Kenya |
| Conditions | Respiratory;Respiratory |
| Interventions | mRNA1273 ;Placebo group |
| Registration date | Jun 12, 2022 |
| Target size | 500 |
| Registry page | pactr.samrc.ac.za |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: